# Plex Research

> Plex Research is a Cambridge, Massachusetts company building an AI-powered scientific intelligence platform for drug discovery. Its proprietary focal graph technology stitches billions of minimally processed experimental data points from genomics, proteomics, chemical biology and clinical sources into a queryable biomedical knowledge graph, then pairs it with large language models so scientists get evidence-backed answers in seconds - every result traceable to the underlying experiments. Trusted by 40+ pharma and biotech teams, Plex helps researchers identify and evaluate drug targets, uncover hidden pharmacology, and, through its AutoPlex agent, run autonomous multi-step research campaigns.

- **Founded:** 2017
- **Headquarters:** Cambridge, Massachusetts, United States
- **Founders:** Douglas Selinger (Founder & Chief Scientific Officer), Brian Gilman (Chief Executive Officer)
- **Team size:** ~9-15 employees
- **Products:** Plex AI Platform, Focal Graph, Target Identification, Target Evaluation, Biomarker Discovery
- **Notable:** Built a biomedical knowledge graph spanning billions of experimental data points, Adopted by 40+ pharma and biotech teams including Pfizer, Merck, Lilly and Takeda, Launched AutoPlex, an autonomous agent-based AI for end-to-end drug discovery campaigns

## Products & services

- **Plex AI Platform** — AI-powered scientific intelligence platform built on a biomedical knowledge graph of billions of minimally processed experimental data points spanning genomics, proteomics, compound activity and clinical trials.
- **Focal Graph** — Proprietary knowledge-graph technology that connects targets, compounds, diseases and pathways and, combined with LLMs, returns evidence-scored answers traceable to source experiments.
- **Target Identification** — Integrates multi-omics evidence to surface novel, druggable disease targets.
- **Target Evaluation** — Multi-dimensional scoring across seven evidence dimensions to de-risk a target before capital commitment.
- **Biomarker Discovery** — Identifies predictive and prognostic biomarkers from integrated experimental data.
- **AutoPlex** — Agent-based AI system that autonomously plans and executes multi-step drug discovery research campaigns - target sweeps, indication expansions and safety profiling - with full transparency into strategy and validation data.
- **Plex API** — Developer access to the biomedical knowledge graph for programmatic queries and integration.
- **Proprietary Data Safe** — Confidential, secure integration of a client's internal experimental data into their private Plex knowledge graph.

## Achievements

- Built a biomedical knowledge graph spanning billions of experimental data points
- Adopted by 40+ pharma and biotech teams including Pfizer, Merck, Lilly and Takeda
- Launched AutoPlex, an autonomous agent-based AI for end-to-end drug discovery campaigns
- Secured a 2025 partnership with Ginkgo Bioworks to study compound mechanisms of action
- Founded on research lineage from George Church's Harvard lab via CSO Douglas Selinger

## Latest updates

- **2025-04** — Announced partnership with Ginkgo Bioworks (Ginkgo Datapoints) to apply the Plex AI Platform to compound mechanism-of-action discovery.
- **2025-01** — Introduced AutoPlex, an agent-based AI system for autonomous, multi-step drug discovery research campaigns combining focal graph technology with LLMs.

## Links

- Website: https://plexresearch.com
- LinkedIn: http://www.linkedin.com/company/plex-research
- YouTube: https://www.youtube.com/watch?v=UB3a5lIfpZQ

---

Profile page: https://yespress.io/plex-research
Published by YesPress — https://yespress.io
Last updated: 2026-07-18